SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Novartis Reports 52-Week Rhapsido Results in Chronic Inducible Urticaria

Novartis announced 52-week results from the Phase III RemIND program evaluating Rhapsido (remibrutinib) for chronic inducible urticaria. The supplied text says the 25 mg twice-daily dose showed early and sustained efficacy through week 52.

NOT
SquawkNews Desk

Related stories

Duffy Says US Air Travel Disruption Will End by Tomorrow Transportation Secretary Sean Duffy told NBC the disruption would be over by the end of today or tomorrow. L impact | EQUITY | Nov 15, 2026, 02:24 PM UTC US Air Travel Disruption Expected to End by Tomorrow, Duffy Says Transportation Secretary Sean Duffy told NBC the US air travel disruption will be over by the end of today or tomorrow. L impact | EQUITY | Nov 15, 2026, 02:05 PM UTC Transportation Secretary Duffy Says US Air Travel Disruption Will End Soon Duffy told NBC the disruption would be over by “end of today, end of tomorrow.” L impact | EQUITY | Nov 15, 2026, 02:05 PM UTC ESS Tech Files for Chapter 7 Bankruptcy and Ceases Operations ESS Tech filed for Chapter 7 bankruptcy and terminated all employees and officers without cause. The iron flow battery company said it took the action after considering available s M impact | EQUITY | Nov 15, 2026, 02:04 PM UTC BMW Recalls 720,796 US Vehicles Over Potential Fire Risk The recall affects several BMW models manufactured between 2012 and 2018. Safety regulators are asking owners to park affected vehicles outside and away from buildings until the pr M impact | EQUITY | Nov 15, 2026, 02:03 PM UTC Cardinal Infrastructure Posts Q3 Loss, Withdraws Guidance and Delays Acquisition Cardinal Infrastructure reported a statutory third-quarter loss of US$0.21 per share and US$202 million in revenue, which was 14% below forecasts. EBITDA margin fell to 4.2%; the c M impact | EQUITY | Nov 15, 2026, 02:03 PM UTC